Johnson & Johnson (JNJ) EBT (2009 - 2026)
Johnson & Johnson (JNJ) posted EBT of $6.7 billion for Q2 2026, up 12.64% sequentially from $6.0 billion in Q1 2026, and up 3.94% YoY from $6.5 billion in Q2 2025.
Johnson & Johnson (JNJ) EBT (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported EBT for 18 years, with the latest figure at $6.7 billion in Q2 2026.
- Quarterly EBT rose 3.94% year-over-year to $6.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $25.2 billion (down 7.87% YoY) and the FY2025 annual result came in at $32.6 billion, up 95.25% from the prior year.
- EBT grew to $6.7 billion in Q2 2026 per JNJ's latest filing, from $6.0 billion in the prior quarter.
- Over five years, EBT peaked at $13.6 billion in Q1 2025 and troughed at -$1.3 billion in Q2 2023.
- A 5-year average of $5.4 billion and a median of $5.2 billion in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2024: EBT plunged 124.74% in 2023, then soared 388.58% in 2024.
- Over 5 years, EBT stood at $5.2 billion in 2022, then slipped by 6.69% to $4.8 billion in 2023, then fell by 19.46% to $3.9 billion in 2024, then rose by 27.76% to $5.0 billion in 2025, then jumped by 35.86% to $6.7 billion in 2026.
- According to Business Quant data, EBT over the past three periods registered $6.7 billion, $6.0 billion, and $5.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 6.75 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 4.28 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -683.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.27 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.80 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.77 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.25 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -653.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 474.95 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 6.75 Bn |
| Mar 29, 2026 | 5.99 Bn |
| Dec 28, 2025 | 4.97 Bn |
| Sep 28, 2025 | 7.49 Bn |
| Jun 29, 2025 | 6.49 Bn |
| Mar 30, 2025 | 13.63 Bn |
| Dec 29, 2024 | 3.89 Bn |
| Sep 29, 2024 | 3.34 Bn |
| Jun 30, 2024 | 5.75 Bn |
| Mar 31, 2024 | 3.71 Bn |
| Dec 31, 2023 | 4.83 Bn |
| Oct 1, 2023 | 5.22 Bn |
| Jul 2, 2023 | 6.31 Bn |
| Apr 2, 2023 | -1.29 Bn |
| Jan 1, 2023 | 3.84 Bn |
| Oct 2, 2022 | 5.17 Bn |
| Jul 3, 2022 | 5.14 Bn |
| Apr 3, 2022 | 5.20 Bn |
| Oct 3, 2021 | 3.85 Bn |
| Jul 4, 2021 | 6.66 Bn |